Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Eric Paul Winer, M.D.

Co-Author

This page shows the publications co-authored by Eric Winer and Nancy Lin.
Connection Strength

15.571
  1. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial. J Clin Oncol. 2020 08 10; 38(23):2610-2619.
    View in: PubMed
    Score: 0.876
  2. A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases. Breast Cancer Res Treat. 2013 Nov; 142(2):405-14.
    View in: PubMed
    Score: 0.556
  3. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol. 2011 Dec; 105(3):613-20.
    View in: PubMed
    Score: 0.472
  4. Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: time to step out of the limelight. J Clin Oncol. 2011 Jan 20; 29(3):251-3.
    View in: PubMed
    Score: 0.455
  5. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009 Feb 15; 15(4):1452-9.
    View in: PubMed
    Score: 0.401
  6. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer. 2008 Nov 15; 113(10):2638-45.
    View in: PubMed
    Score: 0.394
  7. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20; 26(12):1993-9.
    View in: PubMed
    Score: 0.379
  8. Optimizing endocrine therapy for estrogen receptor-positive breast cancer: treating the right patients for the right length of time. J Clin Oncol. 2008 Apr 20; 26(12):1919-21.
    View in: PubMed
    Score: 0.376
  9. Advances in adjuvant endocrine therapy for postmenopausal women. J Clin Oncol. 2008 Feb 10; 26(5):798-805.
    View in: PubMed
    Score: 0.374
  10. Optimal use of aromatase inhibitors: to lead or to follow? J Clin Oncol. 2007 Jul 01; 25(19):2639-41.
    View in: PubMed
    Score: 0.357
  11. Brain metastases: the HER2 paradigm. Clin Cancer Res. 2007 Mar 15; 13(6):1648-55.
    View in: PubMed
    Score: 0.351
  12. Dose density in breast cancer: a simple message? J Natl Cancer Inst. 2005 Dec 07; 97(23):1712-4.
    View in: PubMed
    Score: 0.321
  13. CNS metastases in breast cancer. J Clin Oncol. 2004 Sep 01; 22(17):3608-17.
    View in: PubMed
    Score: 0.294
  14. New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitors. Breast Cancer Res. 2004; 6(5):204-10.
    View in: PubMed
    Score: 0.292
  15. Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings. Breast Cancer Res Treat. 2022 Feb; 192(1):201-210.
    View in: PubMed
    Score: 0.246
  16. Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist. 2021 11; 26(11):927-933.
    View in: PubMed
    Score: 0.240
  17. How we treat HER2-positive brain metastases. ESMO Open. 2021 10; 6(5):100256.
    View in: PubMed
    Score: 0.239
  18. Correction to: Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):305.
    View in: PubMed
    Score: 0.238
  19. Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Res Treat. 2021 Aug; 189(1):203-212.
    View in: PubMed
    Score: 0.233
  20. Weathering the Storm: Managing Older Adults With Breast Cancer Amid COVID-19 and Beyond. J Natl Cancer Inst. 2021 04 06; 113(4):355-359.
    View in: PubMed
    Score: 0.232
  21. Twenty-year risks of breast cancer-specific mortality for stage III breast cancer in the surveillance, epidemiology, and end results registry. Breast Cancer Res Treat. 2021 Jun; 187(3):843-852.
    View in: PubMed
    Score: 0.230
  22. Perceptions of patients with early stage breast cancer toward research biopsies. Cancer. 2021 04 15; 127(8):1208-1219.
    View in: PubMed
    Score: 0.228
  23. Genomic Characterization of de novo Metastatic Breast Cancer. Clin Cancer Res. 2021 02 15; 27(4):1105-1118.
    View in: PubMed
    Score: 0.227
  24. Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Res. 2020 11 30; 22(1):131.
    View in: PubMed
    Score: 0.227
  25. 5th ESO-ESMO international consensus guidelines for advanced breastĀ cancer (ABC 5). Ann Oncol. 2020 12; 31(12):1623-1649.
    View in: PubMed
    Score: 0.224
  26. Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. Ann Oncol. 2020 09; 31(9):1231-1239.
    View in: PubMed
    Score: 0.219
  27. Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. J Clin Oncol. 2020 07 20; 38(21):2390-2397.
    View in: PubMed
    Score: 0.218
  28. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2020 02 13; 382(7):597-609.
    View in: PubMed
    Score: 0.212
  29. Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.211
  30. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. Oncologist. 2019 07; 24(7):e441-e449.
    View in: PubMed
    Score: 0.198
  31. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018 09 20; 36(27):2804-2807.
    View in: PubMed
    Score: 0.192
  32. Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer. NPJ Breast Cancer. 2018; 4:10.
    View in: PubMed
    Score: 0.190
  33. Variation in the use of granulocyte-colony stimulating factor for dose dense paclitaxel: A single institution retrospective study. Breast. 2016 Dec; 30:136-140.
    View in: PubMed
    Score: 0.170
  34. Randomized trial of a physical activity intervention in women with metastatic breast cancer. Cancer. 2016 Apr 15; 122(8):1169-77.
    View in: PubMed
    Score: 0.163
  35. Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers. Breast Cancer Res Treat. 2016 Feb; 155(3):569-78.
    View in: PubMed
    Score: 0.163
  36. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2016 Mar 20; 34(9):945-52.
    View in: PubMed
    Score: 0.162
  37. Variation in the Attitudes of Medical Oncologists Toward Research Biopsies in Patients With Metastatic Breast Cancer. Oncologist. 2015 Sep; 20(9):992-1000.
    View in: PubMed
    Score: 0.157
  38. Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). J Clin Oncol. 2015 Aug 20; 33(24):2623-31.
    View in: PubMed
    Score: 0.156
  39. Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional study. Cancer. 2015 Jun 15; 121(12):1937-48.
    View in: PubMed
    Score: 0.153
  40. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014 Jul 10; 32(20):2142-50.
    View in: PubMed
    Score: 0.145
  41. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 Jul 01; 32(19):2100-8.
    View in: PubMed
    Score: 0.144
  42. Prospective clinical experience with research biopsies in breast cancer patients. Breast Cancer Res Treat. 2013 Nov; 142(1):203-9.
    View in: PubMed
    Score: 0.138
  43. Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer. 2013 Aug; 13(4):254-63.
    View in: PubMed
    Score: 0.136
  44. A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):403-10.
    View in: PubMed
    Score: 0.134
  45. International guidelines for management of metastatic breast cancer (MBC) from the European School of Oncology (ESO)-MBC Task Force: Surveillance, staging, and evaluation of patients with early-stage and metastatic breast cancer. Breast. 2013 Jun; 22(3):203-10.
    View in: PubMed
    Score: 0.134
  46. Attitudes of patients with metastatic breast cancer toward research biopsies. Ann Oncol. 2013 Jul; 24(7):1853-1859.
    View in: PubMed
    Score: 0.133
  47. Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013 Aug; 22(4):525-31.
    View in: PubMed
    Score: 0.132
  48. Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes? Ann Oncol. 2013 Feb; 24(2):283-291.
    View in: PubMed
    Score: 0.129
  49. Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer. 2012 Nov 15; 118(22):5463-72.
    View in: PubMed
    Score: 0.125
  50. 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast. 2012 Jun; 21(3):242-52.
    View in: PubMed
    Score: 0.124
  51. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012 Jun; 133(3):1057-65.
    View in: PubMed
    Score: 0.124
  52. The ethical use of mandatory research biopsies. Nat Rev Clin Oncol. 2011 08 02; 8(10):620-5.
    View in: PubMed
    Score: 0.119
  53. A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer. 2011 Dec; 11(6):376-83.
    View in: PubMed
    Score: 0.118
  54. Heterogeneity of breast cancer and implications of adjuvant chemotherapy. Breast Cancer. 2008; 15(1):31-4.
    View in: PubMed
    Score: 0.093
  55. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs. 2007 Aug; 25(4):369-75.
    View in: PubMed
    Score: 0.088
  56. The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer. Clin Cancer Res. 2022 Apr 01; 28(7):1258-1267.
    View in: PubMed
    Score: 0.062
  57. p16INK4A-deficiency predicts response to combined HER2 and CDK4/6 inhibition in HER2+ breast cancer brain metastases. Nat Commun. 2022 Mar 18; 13(1):1473.
    View in: PubMed
    Score: 0.062
  58. Aiming at a Tailored Cure for ERBB2-Positive Metastatic Breast Cancer: A Review. JAMA Oncol. 2022 Jan 13.
    View in: PubMed
    Score: 0.061
  59. Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? Ann Oncol. 2022 03; 33(3):234-238.
    View in: PubMed
    Score: 0.061
  60. Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer. JCO Precis Oncol. 2021; 5.
    View in: PubMed
    Score: 0.061
  61. Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer. Nat Commun. 2021 09 21; 12(1):5563.
    View in: PubMed
    Score: 0.060
  62. Genomic features of rapid versus late relapse in triple negative breast cancer. BMC Cancer. 2021 May 18; 21(1):568.
    View in: PubMed
    Score: 0.059
  63. Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer: Multidisciplinary Expert Panel and International Society of Geriatric Oncology Consensus Statement. JAMA Oncol. 2021 04 01; 7(4):609-615.
    View in: PubMed
    Score: 0.058
  64. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Res. 2020 11 02; 22(1):120.
    View in: PubMed
    Score: 0.056
  65. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol. 2020 12 20; 38(36):4274-4282.
    View in: PubMed
    Score: 0.056
  66. Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2020 10 01; 6(10):1598-1605.
    View in: PubMed
    Score: 0.056
  67. Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. Breast Cancer Res Treat. 2021 Jan; 185(1):215-227.
    View in: PubMed
    Score: 0.056
  68. Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. Clin Cancer Res. 2020 11 15; 26(22):5974-5989.
    View in: PubMed
    Score: 0.055
  69. The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancer Discov. 2020 08; 10(8):1174-1193.
    View in: PubMed
    Score: 0.055
  70. Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers. Clin Breast Cancer. 2020 10; 20(5):395-401.e3.
    View in: PubMed
    Score: 0.055
  71. Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2556-2564.
    View in: PubMed
    Score: 0.054
  72. Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Ann Oncol. 2020 05; 31(5):590-598.
    View in: PubMed
    Score: 0.054
  73. Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2565-2572.
    View in: PubMed
    Score: 0.054
  74. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann Oncol. 2020 03; 31(3):387-394.
    View in: PubMed
    Score: 0.053
  75. A phase II study of cabozantinib alone or in combination with trastuzumab in breast cancer patients with brain metastases. Breast Cancer Res Treat. 2020 Jan; 179(1):113-123.
    View in: PubMed
    Score: 0.052
  76. Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022. Clin Breast Cancer. 2020 04; 20(2):145-151.e2.
    View in: PubMed
    Score: 0.052
  77. Aggressive Subsets of Metastatic Triple Negative Breast Cancer. Clin Breast Cancer. 2020 02; 20(1):e20-e26.
    View in: PubMed
    Score: 0.052
  78. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
    View in: PubMed
    Score: 0.051
  79. TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol. 2019 05 01; 37(13):1081-1089.
    View in: PubMed
    Score: 0.050
  80. Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nat Genet. 2019 02; 51(2):207-216.
    View in: PubMed
    Score: 0.049
  81. Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer. 2018; 4:22.
    View in: PubMed
    Score: 0.048
  82. Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018 09 10; 36(26):2736-2740.
    View in: PubMed
    Score: 0.048
  83. Breast cancer-specific survival by age: Worse outcomes for the oldest patients. Cancer. 2018 05 15; 124(10):2184-2191.
    View in: PubMed
    Score: 0.047
  84. Drug Resistance in HER2-Positive Breast Cancer Brain Metastases: Blame the Barrier or the Brain? Clin Cancer Res. 2018 04 15; 24(8):1795-1804.
    View in: PubMed
    Score: 0.047
  85. Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States. Breast Cancer Res Treat. 2018 Apr; 168(3):727-737.
    View in: PubMed
    Score: 0.046
  86. Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2018 02 20; 36(6):543-553.
    View in: PubMed
    Score: 0.046
  87. Patterns of Utilization of Imaging Studies and Serum Tumor Markers Among Patients With De Novo Metastatic Breast Cancer. J Natl Compr Canc Netw. 2017 03; 15(3):316-324.
    View in: PubMed
    Score: 0.044
  88. Factors Associated with Early Mortality Among Patients with De Novo Metastatic Breast Cancer: A Population-Based Study. Oncologist. 2017 04; 22(4):386-393.
    View in: PubMed
    Score: 0.044
  89. Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Res Treat. 2016 08; 159(1):151-62.
    View in: PubMed
    Score: 0.042
  90. Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med. 2016 07; 22(7):723-6.
    View in: PubMed
    Score: 0.042
  91. Time trends in incidence rates and survival of newly diagnosed stage IV breast cancer by tumor histology: a population-based analysis. Breast Cancer Res Treat. 2016 06; 157(3):587-96.
    View in: PubMed
    Score: 0.042
  92. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol. 2016 May 01; 34(13):1460-8.
    View in: PubMed
    Score: 0.041
  93. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene. 2016 06 09; 35(23):2961-70.
    View in: PubMed
    Score: 0.040
  94. PI3K-p110a mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene. 2016 07 07; 35(27):3607-12.
    View in: PubMed
    Score: 0.040
  95. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
    View in: PubMed
    Score: 0.040
  96. Racial differences in outcomes for patients with metastatic breast cancer by disease subtype. Breast Cancer Res Treat. 2015 Jun; 151(3):697-707.
    View in: PubMed
    Score: 0.039
  97. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Res Treat. 2014 Aug; 146(3):557-66.
    View in: PubMed
    Score: 0.036
  98. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014 Jul 01; 32(19):2078-99.
    View in: PubMed
    Score: 0.036
  99. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat. 2014 Jun; 145(2):491-501.
    View in: PubMed
    Score: 0.036
  100. Duration and toxicity of adjuvant trastuzumab in older patients with early-stage breast cancer: a population-based study. J Clin Oncol. 2014 Mar 20; 32(9):927-34.
    View in: PubMed
    Score: 0.035
  101. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw. 2014 Jan; 12(1):71-80.
    View in: PubMed
    Score: 0.035
  102. Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. Cancer. 2013 Nov 15; 119(22):3943-51.
    View in: PubMed
    Score: 0.034
  103. Quality of life in long-term survivors of metastatic breast cancer. Clin Breast Cancer. 2012 Apr; 12(2):119-26.
    View in: PubMed
    Score: 0.031
  104. Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jan; 23(1):93-97.
    View in: PubMed
    Score: 0.029
  105. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011 May 15; 17(10):3490-9.
    View in: PubMed
    Score: 0.029
  106. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea. J Clin Oncol. 2010 Jun 20; 28(18):2982-8.
    View in: PubMed
    Score: 0.027
  107. Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction. J Clin Oncol. 2009 Dec 20; 27(36):6117-23.
    View in: PubMed
    Score: 0.026
  108. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel. Cancer Treat Rev. 2008 May; 34(3):223-30.
    View in: PubMed
    Score: 0.023
  109. Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study. Radiology. 2007 Dec; 245(3):824-30.
    View in: PubMed
    Score: 0.023
  110. Tumor therapeutic response and vessel tortuosity: preliminary report in metastatic breast cancer. Med Image Comput Comput Assist Interv. 2006; 9(Pt 2):561-8.
    View in: PubMed
    Score: 0.020
  111. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342. Breast Cancer Res. 2006; 8(6):R66.
    View in: PubMed
    Score: 0.020
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.